English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Triple-negative breast cancer (TNBC) is more than a single disease. Identifying biomarkers to further subdivide TNBC patients with distinct outcome is of great importance. It has been reported that single-nucleotide polymorphisms (SNPs) in Aurora kinase A ( AURKA ) or Aurora kinase B ( AURKB ) are associated with the risk and survival of several cancers. But till now, there is no research about these polymorphisms in TNBC patients.

cancer management and research

Polymorphisms in &lt;em&gt;AURKA&lt;/em&gt; and&lt;em&gt; AURKB&lt;/em&gt; are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy